Open access · CC-BY
via OpenAlex
The unlikely partnership between LRRK 2 and α‐synuclein in Parkinson's disease
Noémie Cresto, Camille Gardier, Francesco Gubinelli, Marie‐Claude Gaillard, Géraldine Liot, West Andrew B, Emmanuel Brouillet
European Journal of Neuroscience · 2018 · ▲ 47 citations
Abstract
Our understanding of the mechanisms underlying Parkinson's disease, the once archetypical nongenetic neurogenerative disorder, has dramatically increased with the identification of α-synuclein and LRRK2 pathogenic mutations. While α-synuclein protein composes the aggregates that can spread through much of the brain in disease, LRRK2 encodes a multidomain dual-enzyme distinct from any other protein linked to neurodegeneration. In this review, we discuss emergent datasets from multiple model systems that suggest these unlikely partners do interact in important ways in disease, both within cells that express both LRRK2 and α-synuclein as well as through more indirect pathways that might involve neuroinflammation. Although the link between LRRK2 and disease can be understood in part through LRRK2 kinase activity (phosphotransferase activity), α-synuclein toxicity is multilayered and plausibly interacts with LRRK2 kinase activity in several ways. We discuss common protein interactors like 14-3-3s that may regulate α-synuclein and LRRK2 in disease. Finally, we examine cellular pathways and outcomes common to both mutant α-synuclein expression and LRRK2 activity and points of intersection. Understanding the interplay between these two unlikely partners in disease may provide new therapeutic avenues for PD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/ejn.14182
- Canonical
- link ↗
- Fetched
- 2026-10-21 MST
Cite this
APA
Cresto, N., Gardier, C., Gubinelli, F., Gaillard, M., Liot, G., B, W.A., & Brouillet, E. (2018). The unlikely partnership between LRRK 2 and α‐synuclein in Parkinson's disease. <em>European Journal of Neuroscience</em>. https://doi.org/10.1111/ejn.14182
Vancouver
Cresto N, Gardier C, Gubinelli F, Gaillard M, Liot G, B WA, et al. The unlikely partnership between LRRK 2 and α‐synuclein in Parkinson's disease. European Journal of Neuroscience. 2018. doi:10.1111/ejn.14182.
BibTeX
@article{nomie2018Theunl,
title = {The unlikely partnership between LRRK 2 and α‐synuclein in Parkinson's disease},
author = {Noémie Cresto and Camille Gardier and Francesco Gubinelli and Marie‐Claude Gaillard and Géraldine Liot and West Andrew B and Emmanuel Brouillet},
journal = {European Journal of Neuroscience},
year = {2018},
doi = {10.1111/ejn.14182},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International Journal of Molecular Sciences 2022
Open access · CC-BY
LRRK2 and Proteostasis in Parkinson’s Disease
Molecular Neurobiology 2012
Open access · CC-BY
Inflammation and α-Synuclein’s Prion-like Behavior in Parkinson's Disease—Is There a Link?
Handbook of clinical neurology 2022
Preprint · OA
T cells, α-synuclein and Parkinson disease
Acta Neuropathologica 2007
Citation only
α-Synuclein pathology in the neostriatum in Parkinson’s disease
Experimental Neurology 2006
Citation only
Plasma α-synuclein is decreased in subjects with Parkinson's disease
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2011
Open access · OA